Evidence map›Paper›PMID 40522436›Full record

ArticleMedical oncology (Northwood, London, England)2025

Efficacy of curcumin-synthesized silver nanoparticles on MCF-7 breast cancer cells.

Azadeh Taherpour, Asghar Zarban, Amir Hassan Asadian, Samira Karbasi, Mehdi Shakibaie

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Azadeh TaherpourStudent Research Committee, Birjand University of Medical Sciences, Birjand, Iran.
Asghar ZarbanDepartment of Clinical Biochemistry, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran.
Amir Hassan AsadianDepartment of Horticultural Science, Faculty of Agriculture, University of Birjand, Birjand, Iran.
Samira KarbasiCardiovascular Diseases Research Center, Birjand University of Medical Sciences, Birjand, Iran.
Mehdi ShakibaieDepartment of Pharmaceutics and Nanotechnology, Faculty of Pharmacy, Birjand University of Medical Sciences, Birjand, Iran. m.shakibaie@bums.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The most common cancer in women worldwide and an important contributor to cancer-related death is breast cancer. Despite advances in treatment, current therapeutic methods remain insufficient, necessitating the development of innovative approaches. Nanotechnology, particularly silver nanoparticles (AgNPs), has emerged as a promising avenue in cancer therapy, offering the ability to target cancer cells through multiple mechanisms. In the current study, we aimed to investigate the anticancer potential of curcumin-biosynthesized AgNPs (C-AgNPs) and their molecular mechanisms on MCF-7 breast cancer cells. Cytotoxicity was assessed using the MTT assay, and the anti-migratory effect was determined through the scratch assay. The molecular mechanisms underlying these effects were investigated using RT-PCR to measure the expression levels of apoptotic-related genes, including P53, BAX, P21, and Bcl-2. Our results showed that C-AgNPs significantly inhibited MCF-7 cell migration. Moreover, gene expression analysis indicated the induction of apoptosis by upregulation of pro-apoptotic genes BAX and P53 and downregulation of Bcl-2. C-AgNPs demonstrated potent cytotoxic and anti-metastatic effects on MCF-7 cells, with the ability to induce apoptosis. C-AgNPs represent a promising candidate for the development of novel breast cancer therapies. However, further research is needed to address this effectiveness.

Indexed as

Antineoplastic AgentsBreast NeoplasmsCurcuminMetal NanoparticlesSilverApoptosisCell MovementCell ProliferationFemaleHumansMCF-7 CellsAntineoplastic AgentsCurcuminSilverAnticancerApoptosisC-AgNPsCurcuminNanoparticleSilver

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.